July 3, 2019

Advent Access today announced receipt of the CE Mark certificate for its award-winning av-Guardian™ vascular access system. The certificate indicates av-Guardian™’s conformity with health, safety, and environmental protection standards set by the European Union for a d...

May 27, 2019

Advent Access, an end-stage renal disease management medical technology company who designed and developed the av-Guardian™ Vascular Access System, is proud to share it has received ISO 13485:2016 certification for its Quality Management System from DEKRA Certification...

March 11, 2019

Founder Ruey Feng PEH spoke with CNBC about our invention, av-Guardian,

as a guardian "guide door" to the arteriovenous  fistula (AVF) that enables reliable access to AVF. 


Link to video >

March 11, 2019

Advent Access, together with our Founder, Ruey Feng Peh, have been selected to join Silicon Valley’s prestigious Stanford StartX Community. Advent is the first medical device startup in Singapore to be selected to join the community of the best Stanford and Silicon Val...

February 18, 2019

Kidney failure patients undergoing hemodialysis suffer numerous needle insertions every week, with each prick running the risk of pain, ineffectiveness and wearing out the target vein.

Medical device startup Advent Access is going after that literal pain-point.



October 27, 2018

The full results of Advent Access's First-In-Human Clinical Trial of the av-Guardian device was released at the American Society of Nephrology (ASN) Kidney Week 2018. The ASN is lauded as the most premier nephrology meeting, involving 13,000 nephrologists and the world...

October 4, 2018

Advent Access is pleased to announce that we have acquired the global manufacturing and commercialization rights to the Vwing™ Vascular Needle Guide product line and other key assets from US company, Vital Access. Our intellectual property portfolio is now one of the m...

September 20, 2018

Advent Access is pleased to announce that our av-Guardian implant technology has completed regulatory submission and key audits for the CE Mark. The clinical trial results used in this submission had also been accepted to be presented at a renowned scientific conferenc...

December 14, 2017

Did you know healthcare systems globally are spending $85 billion annually to sustain dialysis patients? Our founder, Peh Ruey Feng, shares how our lead product av-Guardian can empower patients to experience hemodialysis treatment consistently, comfortably and safely. 


December 11, 2017

Advent Access' fundraise is the largest pre-Series A financing round by a medtech startup in Southeast Asia. New funds will be used to submit CE-mark filing of av-Guardian™ in preparation for global commercialisation and to complete ongoing international clinical trial...

Please reload

Featured Posts

I'm busy working on my blog posts. Watch this space!

Please reload

Recent Posts